Benitec Biopharma Inc. (BNTC) stock
BNTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.15−0.39 (-4.57%)
Close on Nov 17, 2026Market cap $284.29MP/E –Yield –
Earnings
Benitec Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 11, 2027
Q2 FY2027 · estimated, before the open
Revenue, Q1 FY2027
–
EPS, Q1 FY2027
-$0.26
-$0.22 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Benitec Biopharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2027ended Dec 31, 2026 | Feb 11, 2027Expected | – | – | – | – |
| Q1 FY2027ended Sep 30, 2026 | Nov 13, 2026before the open | – | – | -$0.26 | Release |
| Q4 FY2026ended Jun 30, 2026 | Sep 14, 2026after the close | – | – | – | Release |
| Q3 FY2026ended Mar 31, 2026 | May 14, 2026before the open | – | – | -$0.24 | Release |
| Q2 FY2026ended Dec 31, 2025 | Feb 12, 2026before the open | – | – | -$0.26 | Release |
| Q1 FY2026ended Sep 30, 2025 | Nov 14, 2025after the close | – | – | -$0.22 | Release |
| Q4 FY2025ended Jun 30, 2025 | Sep 22, 2025after the close | – | – | – | Release |
| Q3 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | -$0.24 | Release |
| Q2 FY2025ended Dec 31, 2024 | Feb 14, 2025before the open | $0 | – | -$0.33 | Release |
| Q1 FY2025ended Sep 30, 2024 | Nov 14, 2024after the close | $0 | – | -$0.48 | Release |
| Q4 FY2024ended Jun 30, 2024 | Sep 26, 2024after the close | – | – | – | Release |
| Q3 FY2024ended Mar 31, 2024 | May 13, 2024before the open | $0 | -100.0% | -$1.64 | Release |
| Q2 FY2024ended Dec 31, 2023 | Feb 13, 2024before the open | $0 | -100.0% | -$2.64 | Release |
| Q1 FY2024ended Sep 30, 2023 | Nov 13, 2023before the open | $0 | – | -$2.76 | Release |
| Q4 FY2023ended Jun 30, 2023 | Sep 21, 2023before the open | – | – | – | Release |
| Q3 FY2023ended Mar 31, 2023 | May 15, 2023before the open | $54.00K | +12.5% | -$0.16 | Release |
| Q2 FY2023ended Dec 31, 2022 | Feb 13, 2023before the open | $14.00K | -44.0% | -$0.20 | Release |
| Q1 FY2023ended Sep 30, 2022 | Nov 10, 2022before the open | $0 | – | -$0.47 | Release |
| Q4 FY2022ended Jun 30, 2022 | Sep 2, 2022before the open | – | – | – | Release |
| Q3 FY2022ended Mar 31, 2022 | May 16, 2022before the open | $48.00K | – | -$0.40 | Release |
| Q2 FY2022ended Dec 31, 2021 | Feb 14, 2022before the open | $25.00K | – | -$0.59 | Release |
| Q1 FY2022ended Sep 30, 2021 | Nov 15, 2021before the open | $0 | – | -$0.62 | Release |
| Q4 FY2021ended Jun 30, 2021 | Sep 20, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Jun 30, 2020 | Sep 23, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Benitec Biopharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Benitec Biopharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Benitec Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- News
- Update
- Update
- Update
- Results
- Update
- Results
- News
See a number that looks wrong?